Chronic hepatitis virus infections in patients on renal placement therapy

Nephrology Dialysis Transplantation

Volumn 19, Issue 5, 2004, Pages 1049-1053

  Fehr, Thomas ^a,b   Ambühl, Patrice M ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Diagnosis; Dialysis; Hepatitis; Therapy; Transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; ERYTHROPOIETIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; HEPATITIS C VACCINE; IRON; LAMIVUDINE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; BONE MARROW TOXICITY; DISEASE SEVERITY; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; KIDNEY TRANSPLANTATION; LIVER BIOPSY; MENTAL DISEASE; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SEROLOGY; VITAMIN SUPPLEMENTATION;

HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; PREVALENCE; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY;

EID: 2442612829     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh080     Document Type: Editorial

References (27)

1. Denton MD, Singh AK. Recurrent and de novo glomerulonephritis in the renal allograft. Semin Nephrol 2000; 20: 164-175
2. Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int 2003; 63: 2222-2229
3. Huraib SO. Hepatitis C in dialysis patients. Saudi Med J 2003; 24 [Suppl 2]: S123
4. Roth D. Hepatitis C virus: the nephrologist's view. Am J Kidney Dis 1995; 25: 3-16
5. Preikschat P, Gunther S, Reinhold S et al. Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients. Hepatology 2002; 35: 466-477
6. Hayashi PH, Flynn N, McCurdy SA et al. Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus. J Med Virol 1991; 33: 177-180
7. Kowdley KV, Subler DE, Scheffel J, Moore B, Smith H. Hepatitis C virus antibodies in systemic lupus erythematosus. J Clin Gastroenterol 1997; 25: 437-439
8. Abdel-Hamid M, El Daly M, El Kafrawy S et al. Comparison of second- and third-generation enzyme immunoassays for detecting antibodies to hepatitis C virus. J Clin Microbiol 2002; 40: 1656-1659
9. Hanuka N, Sikuler E, Tovbin D et al. Hepatitis C virus infection in renal failure patients in the absence of anti-hepatitis C virus antibodies. J Viral Hepat 2002; 9: 141-145
10. Fehr T, Riehle HM, Nigg L et al. Evaluation of hepatitis B and hepatitis C virus-infected renal allograft recipients with liver biopsy and noninvasive parameters. Am J Kidney Dis 2003; 42: 193-201
11. Imbert-Bismut F, Ratziu V, Pieroni L et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075
12. Mannucci PM, Remuzzi G, Pusineri F et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308: 8-12
13. Rostaing L, Izopet J, Baron E et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426-1431
14. Durlik M, Gaciong Z, Rowinska D el al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transplant Int 1998; 11 [Suppl 1]: S135-S139
15. Baid S, Tolkoff-Rubin N, Saidman S et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-78
16. Ichikawa Y, Kyo M, Hanafusa T et al. A 20-year case study of a kidney transplant recipient with chronic active hepatitis C: clinical course and successful treatment for late acute rejection induced by interferon therapy. Transplantation 1998; 65: 134-138
17. Tang S, Cheng IK, Leung VK et al. Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin. J Hepatol 2003; 39: 875-878
18. Eardley KS, Jones HE, Osman H, Smith SA. Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant 2002; 17: 1982-1987
19. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63: 2215-2234
20. Fabrizi F, Lunghi G, Poordad FF, Martin P. Management of hepatitis B after renal transplantation: an update. J Nephrol 2002; 15: 113-122
21. Kamar N, Sandres-Saune K, Selves J et al. Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184-192
22. Chang KM, Rehermann B, Chisari FV. Immunopathology of hepatitis C. Springer Semin Immunopathol 1997; 19: 57-68
23. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
24. Bruchfeld A, Stahle L, Andersson J, Schvarcz R. Interferon and ribavirin therapy in dialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2001; 16: 1729
25. Fabrizi F, Martin P, Ponticelli C. Hepatitis C virus infection and renal transplantation. Am J Kidney Dis 2001; 38: 919-934
26. Kamar N, Toupance O, Buchler M et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098
27. Cruzado JM, Casanovas-Taltavull T, Torras J et al. Pretransplant Interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360